KG
AXSM icon

Kilter Group’s Axsome Therapeutics AXSM Stock Holding History

Kilter Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170 Buy
+1
New +$173 ﹤0.01% 1491

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kilter Group's AXSM Position: Q1 2026 in Review

Kilter Group opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 1 share worth $170. The stake represents ﹤0.01% of the portfolio and ranks #1491 among its holdings.

409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Kilter Group held 1 share of Axsome Therapeutics worth $170 as of Q1 2026.
  • Axsome Therapeutics was a new Kilter Group position in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q1 2026, its #1491 holding.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Kilter Group's 13F filing for Q1 2026, filed 14 May 2026.